ArticleFrontiers in pharmacology2026
Real-world bleeding risk and molecular interaction profiles of direct oral anticoagulants: a comparative study integrating clinical outcomes and
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Differences in bleeding risk among direct oral anticoagulants (DOACs) may reflect not only exposure-related factors but also molecule-specific drug-target interaction characteristics. This study aimed to evaluate real-world bleeding outcomes and to complement these findings with molecular docking analyses as supportive, hypothesis-generating mechanistic context for safety differences among factor Xa inhibitors and a direct thrombin inhibitor. Methods: A retrospective cohort of 5,721 patients treated with apixaban, rivaroxaban, edoxaban, or dabigatran was analyzed using real-world clinical data. Demographic characteristics, comorbidities, non-life-threatening complications, life-threatening hemorrhagic events, and overall bleeding outcomes were systematically compared. Multivariable logistic regression modeling was used to identify independent predictors of bleeding, with apixaban as the reference agent. Molecular docking analyses were performed using AutoDock 4.2.6 to assess comparative binding energy profiles, hydrogen bond interactions, and root-mean-square deviation values between each DOAC and factor Xa or thrombin. Results: Life-threatening bleeding occurred in 3.1% of patients, while any bleeding event was observed in 13.5% of the cohort. Compared with apixaban, rivaroxaban (OR 1.52), dabigatran (OR 1.29), and edoxaban (OR 1.44) were independently associated with higher odds of bleeding. Advanced age and renal dysfunction were identified as additional independent predictors. Docking analyses indicated that apixaban exhibited the lowest docking-derived binding energy toward factor Xa (ΔG = -14.46 kcal/mol), whereas dabigatran showed selective interaction with thrombin (ΔG = -11.91 kcal/mol). These molecular findings are exploratory and hypothesis-generating and should be interpreted as supportive mechanistic context rather than direct predictors of clinical outcomes. Conclusion: In this retrospective cohort, apixaban was associated with a comparatively lower observed bleeding risk compared with other DOAC agents. Docking findings provide exploratory, hypothesis-generating mechanistic context that may help to contextualize observed clinical patterns.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.